Correlation Engine 2.0
Clear Search sequence regions


  • 1 protein (1)
  • adriamycin (9)
  • akt protein (1)
  • ALDH (1)
  • ALDH1 (9)
  • ALK (195)
  • anti synaptophysin (1)
  • anti- antibodies (4)
  • antibodies (7)
  • apoptosis (10)
  • b cells (5)
  • behavior (1)
  • Ca 3 (1)
  • cancer (6)
  • cancer stem cell (14)
  • cases (18)
  • catalog (1)
  • CD133 (13)
  • CD56 (7)
  • cdna (2)
  • cell clones (2)
  • cell cycle (5)
  • cell numbers (4)
  • cell plates (1)
  • cells d (1)
  • cellular (1)
  • contain (1)
  • data analysis (5)
  • deab (1)
  • denmark (1)
  • density cell (1)
  • diagnosis (2)
  • disease and (1)
  • embryogenesis (1)
  • encyclopedia (4)
  • endometrial carcinoma (86)
  • estrogen (1)
  • ethics committee (1)
  • exons (5)
  • factors (6)
  • flow (4)
  • formalin (1)
  • free (5)
  • g2 m phase (1)
  • GAPDH (1)
  • gene (13)
  • insulin receptor (1)
  • japan (4)
  • kaplan meier method (2)
  • Ki 67 (10)
  • Ki67 (1)
  • layer (2)
  • low (8)
  • lung (2)
  • mitogen (1)
  • mock cells (24)
  • N cadherin (4)
  • nervous system (1)
  • nestin (2)
  • neuroblastoma (2)
  • nonidet p- 40 (1)
  • normal (3)
  • normal endometrium (1)
  • ovarian carcinoma (6)
  • paraffin (1)
  • PARP1 (10)
  • past (1)
  • patients (6)
  • pcr (2)
  • period (1)
  • phase (5)
  • phenotypes (1)
  • phosphatidylinositol (1)
  • plasmids (2)
  • polymer (1)
  • poor prognosis (1)
  • processes (2)
  • prognosis (4)
  • propidium (1)
  • protein gene (1)
  • protein level (1)
  • pvdf (1)
  • reagents (1)
  • risk factors (1)
  • rna (2)
  • rt pcr (2)
  • RTK (1)
  • sds page (1)
  • segment (1)
  • sequence analysis (1)
  • serum (3)
  • signal (5)
  • sodium (2)
  • Sox17 (1)
  • Sox2 (15)
  • Sox3 (1)
  • Sox7 (8)
  • SoxB1 (1)
  • SoxF (1)
  • specimens type (1)
  • STAT (1)
  • stem (1)
  • therapies (1)
  • time death (1)
  • time onset (1)
  • tokyo (2)
  • tp53 gene (1)
  • tumors ovarian (1)
  • western blot (8)
  • women (3)
  • wound (10)
  • XIAP (1)
  • ZEB1 (2)
  • Sizes of these terms reflect their relevance to your search.

    Although anaplastic lymphoma kinase (ALK) is overexpressed in several primary solid tumor types, its role in endometrial carcinoma (Em Ca) remains unclear. We evaluated expression of ALK and its related molecules in clinical samples consisting of 168 Em Ca tissues. We also used Em Ca cell lines to evaluate the functional role of ALK. Cytoplasmic ALK immunoreactivity in the absence of chromosomal rearrangement was positively correlated with ALK mRNA expression, and was significantly higher in Grade (G) 3 Em Ca than in G1 or G2 tumors. ALK immunoreactivity was also significantly associated with expression of cancer stem cell (CSC)-related molecules (cytoplasmic CD133, ALDH1, Sox2) and neuroendocrine markers (CD56 and synaptophysin). Although the proliferative index was significantly higher in ALK-positive Em Ca when compared to ALK- negative malignancies, there was no association between ALK expression and other clinicopathological factors in this disease. In Em Ca cell lines, full-length ALK overexpression increased proliferation, decreased susceptibility to apoptosis, enhanced cancer stem cell features, and accelerated cell mobility, whereas these phenotypes were abrogated in ALK-knockdown cells. Finally, patients with tumors harboring either wild-type ALK or high ALK mRNA expression had a poorer prognosis than those with either mutant ALK or low ALK mRNA expression. Full-length ALK overexpression occurs in a subset of Em Ca, particularly in G3 tumors, and contributes to the establishment and maintenance of aggressive phenotypic characteristics through modulation of several biological processes. © 2023. BioMed Central Ltd., part of Springer Nature.

    Citation

    Ako Yokoi, Yusaku Nakamura, Miki Hashimura, Yasuko Oguri, Toshihide Matsumoto, Mayu Nakagawa, Yu Ishibashi, Takashi Ito, Kensuke Ohhigata, Youhei Harada, Naomi Fukagawa, Makoto Saegusa. Anaplastic lymphoma kinase overexpression enhances aggressive phenotypic characteristics of endometrial carcinoma. BMC cancer. 2023 Aug 17;23(1):765

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 37592266

    View Full Text